If you’ve been taking an antidepressant but still don’t feel like yourself, you’re not alone. Many people with major depressive disorder (MDD) experience only partial relief from their current medication.
A newer option, Caplyta (lumateperone), has recently been approved by the FDA as an add-on (adjunctive) treatment for depression—offering another path forward when antidepressants alone aren’t enough.
What is Caplyta?
Caplyta is a prescription medication originally approved for:
– Schizophrenia and Bipolar depression (monotherapy and adjunct)
It’s part of a class of medications called atypical antipsychotics, but in lower doses and specific combinations, medications in this class are often used to enhance the effects of antidepressants.
Caplyta for Depression (Major Depressive Disorder)
Caplyta is now approved to be used together with an antidepressant in adults with major depressive disorder.
Adding Caplyta to an antidepressant can help:
– Improve mood, including depression and anxiety
– Reduce lingering symptoms
– Support overall functioning
How Caplyta Works?
Unlike traditional antidepressants that mainly affect serotonin, Caplyta works across multiple brain systems:
– Serotonin (mood regulation)
– Dopamine (motivation, reward, focus)
– Glutamate (cognition and neural signaling)
This broader mechanism may be one reason it can help when standard treatments fall short.
Caplyta Dosing
It comes in three doses: 10.5 mg, 21 mg, and 42 mg.
Can be taken with or without food.
Best if taken at bedtime as it can be sedating.
If you have liver condition, your provider may opt for the lower dose.
Common Side Effects of Caplyta
Most people tolerate Caplyta well, but like any medication, it can cause side effects.
Most common side effects are:
– Sedation (sleepiness and fatigue and that is why it is best taken at bedtime)
– Dizziness
– Nausea
– Diarrhea
– Dry mouth
What Makes it Different?
Compared to many similar medications, Caplyta tends to have:
– Lower risk of weight gain
– Minimal impact on cholesterol and blood sugar
– Low risk of movement-related side effects (like restlessness or stiffness)
– Tardive dyskinesia (possible but low risk compared to other antipsychotics)
Final Thoughts
Caplyta offers a new, well-tolerated option for people who need more than an antidepressant alone. For the right patient, it can help bridge the gap between partial improvement and feeling like yourself again.
If you’re struggling with persistent symptoms of depression, it may be worth discussing whether an adjunctive treatment approach is appropriate for you.
Leave a Reply